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From Deep Pearl Diving to EnlightenmentJagat Narula, MD, PHD,* Vasken Dilsizian, MD,y Y. Chandrashekhar, MDzD espite major advances in the managementof acute coronary syndromes, post-infarctmorbidity has not been adequately con-
tained. The incidence of heart failure in the aftermath
of myocardial infarction (MI) continues to be sizable,
and attempts have been made toward the develop-
ment of various structural patterns and morpholog-
ical algorithms that may help identify subjects who
are at higher risk for adverse ventricular remodeling
and heart failure.
However, while this has been important, one could
argue that it has offered limited success, and deﬁning
adverse left ventricular structure and function
through morphofunctional imaging schemes can do
only so much. Although remodeling predicts subop-
timal prognosis, we have reached the limit of what it
can do, and deﬁning therapy on the basis of
morphological or functional imaging has not been
helpful in preventing heart failure. In contrast, mo-
lecular imaging, at least in experimental milieu, has
allowed better understanding of the remodeling
process and opportunity for intervention. Such a
modality of evaluation has characterized the extent
of myocardial damage by the processes of necrosis
and apoptosis (and resolution thereof) and estimated
the rate of myoﬁbroblastic proliferation. Recently,
substantial information has become available per-
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the contents of this paper to disclose.immune system in the repair of infarcted myocar-
dium, which is highly variable, and relatively deﬁ-
cient or exaggerated immune responses may variably
contribute to remodeling. Because the dose of the
immune response determines the protective or
detrimental inﬂuence on remodeling, the authors
of 2 reports published in this issue of iJACC (1,2)
propose that immune surveillance for tissue repair
post-MI can be a powerful strategy to detect, treat,
and predict prognosis, even for conditions that have
not traditionally been thought to be in the purview
of imaging (3). This might change our concepts from
the traditional patient with dilated or not dilated
left ventricles, and reduced or preserved ejection
fraction to more meaningful connotations, such as
at high risk for damage versus not at high risk for
myocardial damage, or efﬁcient versus inefﬁcient
repairers.
Molecular imaging has been widely applied to
differentiate between myocardial cell death in
MI attributed to the necrotic and apoptotic pro-
cesses. Tracers targeting heavy chains of myosin or
abundant intracellular heat-shock proteins in the
ischemic myocardium have allowed the distinct
deﬁnition of myocardial necrosis (4,5). In contrast,
targeting of cell surface phospholipid alterations by
radiolabeled annexin A5 (6) or duramycin (unpub-
lished observations) deﬁnes the apoptotic process.
Imaging studies targeting 2 modes of cell death
have clariﬁed the concept of the nonphysiological
apoptotic process, which precedes the onset of
necrosis and is reversible upon the resolution of
ischemia or restricting apoptotic cycling (7). These
studies have clearly demonstrated that the 2 modes
of cell death are part of the same spectrum, and an
attempt to limit either of them would restrict all
kinds of cell death. Imaging studies have also
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1473demonstrated that the annexin A5 is internalized
into the injured cells and inﬂuences the cellular
rescue.
Extracellular myocardial repair by replacement
ﬁbrosis at the site of necrotic debris and the untoward
occurrence of interstitial ﬁbrosis in the peri-infarct
and remote myocardium have been evaluated by
the distribution of enzymes involved in the synthesis
and degradation of collagen ﬁbers and the rate
of myoﬁbroblastic proliferation. Because collagen
deposition and interstitial ﬁbrosis contribute to car-
diac remodeling and heart failure after MI, evaluation
of myoﬁbroblastic proliferation should provide indi-
rect evidence of the extent of ﬁbrosis. Molecular im-
aging with a charged radiolabeled RGD peptide with
afﬁnity to myoﬁbroblast integrin receptors demon-
strated that maximum tracer uptake occurred at
2 weeks in the infarct zone, reducing gradually by
12 weeks (8). In contrast, uptake started to increase
in the remote areas by 12 weeks. Tracer uptake was
histologically conﬁrmed to bind to myoﬁbroblasts
and was directly related to the new collagen pro-
duction. Quantitative uptake decreased signiﬁcantly
in animals treated with any of the angiotensin-
converting enzyme inhibitors, angiotensin receptor
blockers, or aldosterone receptor antagonists (9).
Intervention with 2 or 3 of these neurohumoral an-
tagonists demonstrated further reduction in tracer
uptake. The reduced new collagen in the remote
area in response to neurohumoral inhibition sug-
gested the beneﬁcial effect. However, the decrease
in new collagen synthesis in the infarcted area was
not affected in the face of massive replacement
collagen content, but suppression of the renin-
angiotensin-aldosterone axis allowed rapid matura-
tion of thin to thick collagen ﬁbers in this area and
prevented aneurysmal dilation.
The studies reported in this issue have used a
gallium-68 based positron emission tomographic
tracer, pentixafor, that binds to CXCR4 chemokine
receptor. Paired CXCR4 and its ligand, SDF-1,
regulate the migration of hematopoietic stem cells,
as well as neutrophils and monocytes from bone
marrow and spleen (3). These cells provide balanced
inﬂammatory, phagocytic, and reparative responses,
wherein excess or deﬁciency of any component
may adversely affect subsequent remodelingprocess (10). Although inﬂammatory cell imaging
has previously been proposed indirectly and
less speciﬁcally with 18F-ﬂuorodeoxyglucose and
18F-ﬂuorothymidine (11), pentixafor uptake was seen
in the infarcted region early after the event (2), was
blocked effectively by a CXCR4 inhibitor, and
was substantially reduced by neurohumoral antag-
onists (3). Not all infarcted segments were pentix-
afor positive, and the maximum uptake was
observed in signiﬁcantly damaged myocardial seg-
ments. High tracer uptake in marrow and spleen
was correlated with signal intensity in the myocar-
dium. Although longitudinal studies are necessary,
these observations suggest that lower signal might
support better outcomes and the higher up-
take might be an indication for anti-inﬂammatory
intervention.
From the aforementioned reports of molecular
imaging in acute MI and during the clinical course
thereafter, it becomes clear that regardless of clin-
ical applicability, these techniques clarify patho-
genesis in real time, because molecular imaging is
the only strategy that allows interrogation of path-
ophysiological processes at the subcellular level in a
living organism. It is necessary to identify appro-
priate targets and design appropriate targeting
tracer. With better imaging comes better under-
standing of pathogenetic mechanisms and recogni-
tion of yet better targets and hence yet better
understanding (12–14). The future of imaging will be
not just showing more about chamber or scar size
and patterns or just more sensitive measures of
myocardial dysfunction—we have reached a plateau
for what we can learn from that. It is a distinct
possibility that molecular imaging might be able to
dynamically uncover what pathways are activated
in damage and repair (personalized imaging), and
which of those are to be targeted for therapy
(personalized therapy). We have said it in the past
(12–14) and would like to re-emphasize that molec-
ular imaging is all about unraveling deep-seated
clues and all about better learning.
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